The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Mosapride     4-amino-5-chloro-2-ethoxy-N- [[4-[(4...

Synonyms: CHEMBL60889, SureCN16417, Mosart (TN), AGN-PC-00F93S, ANW-42285, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Mosapride

 

Psychiatry related information on Mosapride

  • During the day hours (0700-1900, light on), the local infusion of either 5-HT4 agonist, 5-MeOT (100 microM) or mosapride (10 microM), but not in their lower concentrations, into the bilateral hippocampus significantly increased motor activity as compared with the baseline values or the control rats [6].
 

High impact information on Mosapride

 

Chemical compound and disease context of Mosapride

 

Biological context of Mosapride

 

Anatomical context of Mosapride

 

Associations of Mosapride with other chemical compounds

 

Gene context of Mosapride

 

Analytical, diagnostic and therapeutic context of Mosapride

  • Improvement of glycemic control after treatment with mosapride for diabetic gastropathy [26].
  • In ancillary experiments 10 rats received 100 mg/kg mosapride orally or placebo 50 minutes before intraperitoneal injection of 10 mg/kg morphine, followed 20 minutes later by injection of naloxone, and the respiratory frequency was monitored [2].
  • In conscious dogs with force transducers implanted, mosapride (0.3-3 mg/kg i.v.) stimulated the antral motility without affecting the colonic motility [27].
  • Mosapride citrate prolongs survival in stroke patients with gastrostomy [28].
  • In order to analyze simultaneously the enantiomers of mosapride and M-1 in plasma, a simple and reproducible high-performance liquid chromatographic (HPLC) method has been developed [29].

References

  1. Mosapride, a 5HT-4 receptor agonist, improves insulin sensitivity and glycaemic control in patients with Type II diabetes mellitus. Ueno, N., Inui, A., Asakawa, A., Takao, F., Komatsu, Y., Kotani, K., Nishimura, R., Kasuga, M. Diabetologia (2002) [Pubmed]
  2. The 5-hydroxytryptamine 4 receptor agonist mosapride does not antagonize morphine-induced respiratory depression. Lötsch, J., Skarke, C., Schneider, A., Hummel, T., Geisslinger, G. Clin. Pharmacol. Ther. (2005) [Pubmed]
  3. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Ruth, M., Hamelin, B., Röhss, K., Lundell, L. Aliment. Pharmacol. Ther. (1998) [Pubmed]
  4. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Hallerbäck, B.I., Bommelaer, G., Bredberg, E., Campbell, M., Hellblom, M., Lauritsen, K., Wienbeck, M., Holmgren, L.L. Aliment. Pharmacol. Ther. (2002) [Pubmed]
  5. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Liu, Z., Sakakibara, R., Odaka, T., Uchiyama, T., Uchiyama, T., Yamamoto, T., Ito, T., Asahina, M., Yamaguchi, K., Yamaguchi, T., Hattori, T. Mov. Disord. (2005) [Pubmed]
  6. 5-HT4 receptors in the hippocampus modulate rat locomotor activity. Takahashi, H., Takada, Y., Urano, T., Takada, A. Hippocampus. (2002) [Pubmed]
  7. Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia. Kinoshita, Y., Hashimoto, T., Kawamura, A., Yuki, M., Amano, K., Sato, H., Adachi, K., Sato, S., Oshima, N., Takashima, T., Kitajima, N., Abe, K., Suetsugu, H. Aliment. Pharmacol. Ther. (2005) [Pubmed]
  8. Stimulatory action of itopride hydrochloride on colonic motor activity in vitro and in vivo. Tsubouchi, T., Saito, T., Mizutani, F., Yamauchi, T., Iwanaga, Y. J. Pharmacol. Exp. Ther. (2003) [Pubmed]
  9. A 5-HT4 agonist mosapride enhances rectorectal and rectoanal reflexes in guinea pigs. Shimatani, H., Kojima, Y., Kadowaki, M., Nakagawa, T., Fujii, H., Nakajima, Y., Takaki, M. Am. J. Physiol. Gastrointest. Liver Physiol. (2003) [Pubmed]
  10. Teratogenicity of the I(Kr)-blocker cisapride: relation to embryonic cardiac arrhythmia. Sköld, A.C., Danielsson, C., Linder, B., Danielsson, B.R. Reprod. Toxicol. (2002) [Pubmed]
  11. In vivo assessment of acceleration of motor activity associated with acetylcholine release via 5-hydroxytryptamine4 receptor in dog intestine. Makimoto, N., Sakurai-Yamashita, Y., Furuichi, A., Kawakami, S., Enjoji, A., Kanematsu, T., Taniyam, K. Jpn. J. Pharmacol. (2002) [Pubmed]
  12. Torsades de pointes ventricular tachycardia induced by mosapride and flecainide in the presence of hypokalemia. Ohki, R., Takahashi, M., Mizuno, O., Fujikawa, H., Mitsuhashi, T., Katsuki, T., Ikeda, U., Shimada, K. Pacing and clinical electrophysiology : PACE. (2001) [Pubmed]
  13. Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. Madan, K., Ahuja, V., Kashyap, P.C., Sharma, M.P. Dis. Esophagus (2004) [Pubmed]
  14. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? Carlsson, L., Amos, G.J., Andersson, B., Drews, L., Duker, G., Wadstedt, G. J. Pharmacol. Exp. Ther. (1997) [Pubmed]
  15. Effects of gastroprokinetic agents on gastroparesis in streptozotocin-induced diabetic rats. Yamano, M., Kamato, T., Nagakura, Y., Miyata, K. Naunyn Schmiedebergs Arch. Pharmacol. (1997) [Pubmed]
  16. Influence of mosapride citrate on gastric motility and autonomic nervous function: evaluation by spectral analyses of heart rate and blood pressure variabilities, and by electrogastrography. Endo, J., Nomura, M., Morishita, S., Uemura, N., Inoue, S., Kishi, S., Kawaguchi, R., Iga, A., Ito, S., Nakaya, Y. J. Gastroenterol. (2002) [Pubmed]
  17. Effects of mosapride, a 5-hydroxytryptamine 4 receptor agonist, on electrical activity of the small intestine and cecum in horses. Sasaki, N., Okamura, K., Yamada, H. Am. J. Vet. Res. (2005) [Pubmed]
  18. Effect of mosapride on glycemic control and gastric emptying in type 2 diabetes mellitus patients with gastropathy. Asakawa, H., Hayashi, I., Fukui, T., Tokunaga, K. Diabetes Res. Clin. Pract. (2003) [Pubmed]
  19. The effect of mosapride on esophageal motility and bolus transit in asymptomatic volunteers. Cho, Y.K., Choi, M.G., Han, H.W., Park, J.M., Oh, J.H., Jeong, J.J., Cho, Y.S., Lee, I.S., Kim, S.W., Choi, K.Y., Chung, I.S. J. Clin. Gastroenterol. (2006) [Pubmed]
  20. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K(+) channel. Potet, F., Bouyssou, T., Escande, D., Baró, I. J. Pharmacol. Exp. Ther. (2001) [Pubmed]
  21. The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: comparison with cisapride and mosapride citrate. Mushiroda, T., Douya, R., Takahara, E., Nagata, O. Drug Metab. Dispos. (2000) [Pubmed]
  22. Quantification of fexofenadine in human plasma by liquid chromatography coupled to electrospray tandem mass spectrometry using mosapride as internal standard. Nirogi, R.V., Kandikere, V.N., Shukla, M., Mudigonda, K., Maurya, S., Komarneni, P. Biomed. Chromatogr. (2007) [Pubmed]
  23. Effects of mosapride citrate on human plasma levels of motilin, gastrin, somatostatin, and secretin. Itoh, H., Nagano, T., Takeyama, M. Biol. Pharm. Bull. (2001) [Pubmed]
  24. Pharmacological characterization of a novel 5-HT4 receptor agonist, TS-951, in vitro. Kajita, S., Ito, C., Kawamura, R., Yasuda, S., Isobe, Y., Fukushima, K. Pharmacology (2001) [Pubmed]
  25. Mosapride improves food intake, while not worsening glycemic control and obesity, in ob/ob obese mice with decreased gastric emptying. Asakawa, A., Ueno, N., Katagi, M., Ijuin, Y., Morita, Y., Mizuno, S., Inui, T., Sakamaki, R., Shinfuku, N., Uemoto, M. J. Diabetes Complicat. (2006) [Pubmed]
  26. Improvement of glycemic control after treatment with mosapride for diabetic gastropathy. Koshiyama, H., Shimono, D., Wada, Y., Nakamura, Y. Diabetes Care (2000) [Pubmed]
  27. Comparison of effect of mosapride citrate and existing 5-HT4 receptor agonists on gastrointestinal motility in vivo and in vitro. Mine, Y., Yoshikawa, T., Oku, S., Nagai, R., Yoshida, N., Hosoki, K. J. Pharmacol. Exp. Ther. (1997) [Pubmed]
  28. Mosapride citrate prolongs survival in stroke patients with gastrostomy. He, M., Ohrui, T., Ebihara, T., Ebihara, S., Sasaki, H., Arai, H. Journal of the American Geriatrics Society (2007) [Pubmed]
  29. Simultaneous enantiomeric determination of a gastroprokinetic agent mosapride citrate and its metabolite in plasma using alpha 1-acid glycoprotein HPLC column. Yokoyama, I., Mizuki, Y., Yamaguchi, T., Fujii, T. Journal of pharmaceutical and biomedical analysis. (1997) [Pubmed]
 
WikiGenes - Universities